Respiratory Syncytial Virus (RSV) Diagnostic Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 10.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Respiratory Syncytial Virus (RSV) Diagnostic Market Analysis
The respiratory syncytial virus (RSV) diagnostic market is expected to register a significant CAGR of 10.1% during the study period.
- Although COVID-19 led to a shortage in essential diagnostic tests during the early pandemic, multiplex diagnostics have played an important role in providing quick results for COVID-19 diagnostics. However, the launch of products is propelling the growth of the market. For instance, in February 2022, Avellino Labs USA Inc. launched AvellinoCoV2 - Respiratory Test, a multi-panel RT-PCR-based virus assay that accurately detects four viral infections in one patient sample - COVID-19, respiratory syncytial virus (RSV), influenza A and influenza B. Thus, COVID-19 has slightly declined during the early pandemic due to lockdown restrictions. However, the market was positively impacted during the late pandemic due to a rise in testing for RSV and saw a significant surge post-pandemic due to the launch of new tests, and it is expected to boost the market's growth over the period.
- The factors propelling the studied market growth are the growing burden of respiratory syncytial virus infections globally, rise in investments, technological advancements in the development of RSV diagnostic tests, product approvals and launches, and other key strategies adopted by the market players.
- According to the Center for Disease Control and Prevention (CDC) update in July 2023, the overall rate of RSV-associated hospitalizations was 50.9 per 100,000 people in the United States in the 2022-2023 season. Such a huge rate of hospitalization is anticipated to increase the adoption of testing for RSV infections, driving the market growth.
- The launch of products for the effective diagnosis of RSV infections is expected to boost the studied market growth due to the increased availability of products in the market. For instance, in November 2021, QIAGEN launched the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test for the QIAstat-Dx system to quickly identify whether patients have common seasonal respiratory infections or SARS-CoV-2. Additionally, in September 2021, Roche launched three molecular polymerase chain reaction (PCR) diagnostic test panels to detect and differentiate common respiratory pathogens at the same time, which include influenza A, influenza B, and respiratory syncytial virus (RSV); adenovirus (ADV), human metapneumovirus (hMPV) and enterovirus/rhinovirus (EV/RV); and parainfluenza 1, 2, 3 and 4.
- Moreover, key initiatives adopted by key market players are expected to propel market growth significantly. In February 2022, Seegene Inc. signed a supply deal with the Ministry of Health of Brazil to deliver four million Allplex SARS-CoV-2/FluA/FluB/RSV Assay, capable of identifying respiratory viruses, including COVID-19, Flu A/B as well as RSV in a single test. Such steps will boost the studied market growth during the study period due to the rise in adoption.
- Therefore, owing to factors such as the rising incidence of RSV and key initiatives adopted by the market players, the studied market is expected to grow significantly during the study period. However, strict regulatory norms and low detection limits of immunoassays are expected to hinder the market growth during the study period.
Respiratory Syncytial Virus (RSV) Diagnostic Market Trends
Rapid Antigen Detection Tests Segment is Expected to Account for the Significant Market Share During the Forecast Period
- A rapid antigen test (RAT), sometimes called a rapid antigen detection test (RADT) or rapid antigen test (ART), is a rapid diagnostic test suitable for point-of-care testing that directly detects the presence or absence of an antigen.
- These tests provide results within 15 to 30 minutes, require minimal training or infrastructure, and have significant cost advantages. RATs are based on the principle of antigen-antibody interaction. Antigen-antibody reactions are a mainstay for the rapid detection of proteins. Antibodies recognize proteins based on their structure as well as their content. They can be very specific, binding to only a small part of an antigen and discriminating between highly similar antigens. Older adults are at greater risk than young adults for serious complications from RSV because of their poor immune systems.
- The rising research and development for the development of rapid antigen tests, rising product launches, and key initiatives taken by market players and the government are expected to boost the segment growth during the study period. According to the study published in the Journal of Infectious Diseases in February 2022, the positive percentage agreement of Xpert Xpress Flu/RSV, a rapid antigen test, compared to routine RT-PCR, is high for RSV detection in home-dwelling older adults. The assay is fast and easy to use at the point of care. Such advantages of RATs will propel the segment's growth.
- Furthermore, the rising investments to boost product development and business expansions in the studied segment will drive the segment growth. For instance, in March 2021, the National Institute of Health launched a Rapid Acceleration of Diagnostics Tech (RADx) initiative, with a total investment of USD 29.3 million focusing on increasing testing capacity at the point-of-care settings. Further, through this investment, Meridian Biosciences is developing a respiratory panel that includes SARS-CoV-2, Influenza A/B, and RSV in one test. Additionally, in March 2021, Quidel Corporation opened a new manufacturing facility in Carlsbad, California, that will be dedicated to the production of the QuickVue line of products, which includes a rapid test for Influenza, RSV, Strep A, and other diseases and conditions.
- Thus, due to the above-mentioned factors, the studied segment is expected to contribute to the significant growth of the market.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period
- The primary driving factors for the growth of the North American respiratory syncytial virus (RSV) market are the growing burden of cold and pneumonia in the region, growing research and development activities, supporting government initiatives such as approvals for RSV diagnostics and initiatives taken by the key market players.
- The United States within North America is expected to hold a significant share of the studied market during the study period due to the rising hospitalizations for RSV, rising approval of products from regulatory agencies, and the strong foothold of key market players. For instance, according to the Centers for Disease Control and Prevention, in June 2021, in the United States, RSV accounts for approximately 58,000 hospitalizations among children younger than 5 years old and 177,000 hospitalizations among adults aged 65 years or older every year. Thus, the rising hospitalizations for RSV infections are anticipated to boost the demand for RSV diagnostics, driving market growth.
- Moreover, product approvals in the regions will also boost the diagnostic procedures in the region. For instance, in May 2022, the United States Food and Drug Administration (US FDA) authorized the LabCorp Seasonal Respiratory Virus RT-PCR DTC test for use without a prescription by individuals with symptoms of respiratory viral infection consistent with COVID-19. Additionally, in December 2021, Applied BioCode received Emergency Use Authorization (EUA) from the US FDA for its BioCode CoV-2 Flu Plus Assay. This PCR-based, multiplex molecular diagnostic assay can simultaneously detect and differentiate between SARS-CoV-2, Influenza A with subtypes (seasonal H1, 2009 H1N1, H3, Influenza B), and Respiratory Syncytial Virus (RSV) in nasopharyngeal swab specimens.
- Furthermore, in January 2022, Under Health Canada's Interim Order, Seegene Inc. received approval for its Allplex SARS CoV-2 FluA/FluB/RSV Assay. The Allplex SARS CoV-2 FluA/FluB/RSV Assay from Seegene is a multiplex real-time PCR assay that allows for both amplification and differentiation of respiratory symptoms. It can distinguish between Influenza A, B, RSV, and COVID-19 in a single test.
- Therefore, the key strategies adopted by the market players, along with the rising hospitalization due to RSV in the region, are expected to lead to lucrative growth of the market in North America.
Get Analysis on Important Geographic Markets
Download PDF
Respiratory Syncytial Virus (RSV) Diagnostic Industry Overview
The respiratory syncytial virus (RSV) diagnostic market is moderately competitive, with the presence of several players. The factors owing to the competition include strategies such as acquisitions, partnerships, distribution agreements, and others that are readily adopted by key market players to boost the market. Some players operating in the market are BioMerieux SA, Becton, Dickinson and Company, Abbott, F. Hoffmann-La Roche Ltd, ThermoFisher Scientific Inc., and others.
Respiratory Syncytial Virus (RSV) Diagnostic Market Leaders
-
bioMerieux SA
-
Becton, Dickinson and Company
-
F. Hoffmann-La Roche Ltd
-
ThermoFisher Scientific Inc.
-
Abbott Laboratories
*Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
Respiratory Syncytial Virus (RSV) Diagnostic Market News
- February 2023: Becton, Dickinson, and Company received Emergency Use Authorization (EUA) from the Food and Drugs Administration (FDA) for its product BD MAX Molecular Diagnostic System combo test for SARS-CoV-2, influenza A + B and the respiratory syncytial virus.
- January 2023: Sonora Quest Laboratories launched qualitative, multi-target, molecular diagnostics testing that uses a patient sample to aid in detecting COVID-19, respiratory syncytial virus (RSV), and influenza.
Respiratory Syncytial Virus (RSV) Diagnostic Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Burden of Syncytial Virus Infections
- 4.2.2 Increasing Approvals for Syncytial Virus Diagnostic Products
-
4.3 Market Restraints
- 4.3.1 Stringent Regulations and Low Detection Limits of Immunoassays
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD)
-
5.1 By Product
- 5.1.1 Kits and Assays
- 5.1.2 Instruments
- 5.1.3 Other Products
-
5.2 By Method
- 5.2.1 Molecular Diagnostics
- 5.2.2 Rapid Antigen Detection Tests
- 5.2.3 Immunoassays
- 5.2.4 Flow Cytometry
- 5.2.5 Chromatography
- 5.2.6 Other Methods
-
5.3 By End-User
- 5.3.1 Hospitals and Clinics
- 5.3.2 Clinical Laboratories
- 5.3.3 Other End-Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 bioMerieux SA
- 6.1.2 Becton, Dickinson and Company
- 6.1.3 Abbott Laboratories
- 6.1.4 F. Hoffmann-La Roche Ltd
- 6.1.5 ThermoFisher Scientific Inc.
- 6.1.6 Luminex Corporation
- 6.1.7 Qiagen
- 6.1.8 Hologic Inc.
- 6.1.9 DiaSorin Inc.
- 6.1.10 Bio-Rad Laboratories Inc.
- 6.1.11 Merck KGaA
- 6.1.12 BioCartis
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To Availablity**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
Respiratory Syncytial Virus (RSV) Diagnostic Industry Segmentation
Respiratory syncytial virus (RSV) is a virus that causes respiratory infections such as bronchiolitis and pneumonia. The symptoms of the disease usually include runny nose, sneezing, coughing, and fever.
The respiratory syncytial virus (RSV) diagnostic market is segmented by product (kits and reagents, instruments, and other products), method (molecular diagnostics, rapid antigen detection tests, immunoassays, flow cytometry, and chromatography), end-user (hospitals and clinics, clinical laboratories, and other end-users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD) for the above-mentioned segments.
| By Product | Kits and Assays | |
| Instruments | ||
| Other Products | ||
| By Method | Molecular Diagnostics | |
| Rapid Antigen Detection Tests | ||
| Immunoassays | ||
| Flow Cytometry | ||
| Chromatography | ||
| Other Methods | ||
| By End-User | Hospitals and Clinics | |
| Clinical Laboratories | ||
| Other End-Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Need A Different Region Or Segment?
Customize Now
Respiratory Syncytial Virus (RSV) Diagnostic Market Research FAQs
What is the current Global Respiratory Syncytial Virus (RSV) Diagnostic Market size?
The Global Respiratory Syncytial Virus (RSV) Diagnostic Market is projected to register a CAGR of 10.10% during the forecast period (2024-2029)
Who are the key players in Global Respiratory Syncytial Virus (RSV) Diagnostic Market?
bioMerieux SA, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, ThermoFisher Scientific Inc. and Abbott Laboratories are the major companies operating in the Global Respiratory Syncytial Virus (RSV) Diagnostic Market.
Which is the fastest growing region in Global Respiratory Syncytial Virus (RSV) Diagnostic Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Respiratory Syncytial Virus (RSV) Diagnostic Market?
In 2024, the North America accounts for the largest market share in Global Respiratory Syncytial Virus (RSV) Diagnostic Market.
What years does this Global Respiratory Syncytial Virus (RSV) Diagnostic Market cover?
The report covers the Global Respiratory Syncytial Virus (RSV) Diagnostic Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Respiratory Syncytial Virus (RSV) Diagnostic Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Respiratory Syncytial Virus (RSV) Diagnostic Industry Report
Statistics for the 2024 Respiratory Syncytial Virus (RSV) Diagnostic market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Respiratory Syncytial Virus (RSV) Diagnostic analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Respiratory Syncytial Virus (RSV) Diagnostic Market Report Snapshots
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
